A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors

NCT05351502 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Nitric Oxide 25,000 ppm
DRUG: Nitric Oxide 50,000 ppm
DRUG: Nitric Oxide 100,000 ppm
DRUG: Nitric Oxide selected dose

Sponsor

Beyond Air Inc.